| Literature DB >> 29748583 |
Xi Xiong1, Ya-Nan He1, Bi Feng1, Yuan Pan2, Hai-Zhu Zhang3, Xiu-Mei Ke1, Yi Zhang4, Ming Yang5, Li Han6, Ding-Kun Zhang7.
Abstract
Nowadays, breast disorders seriously affect women's health in an increasing number. In China, Xiaojin Pills are commonly used in the treatment of breast diseases. Doctors have concluded that the combined use of Xiaojin Pills with conventional therapy can significantly improve the efficacy with fewer side effects. However, the prescription of Xiaojin Pills is complicated and their quality control methods cannot completely ensure the quality of Xiaojin Pills. On the basis of its mechanism, our study combined chemical evaluation and biological evaluation to identify the anti-inflammatory markers of Xiaojin Pills. In this manuscript, 13 compounds in Xiaojin Pills were quantified. At the same time, the cyclooxygenase-2 inhibition rates of different Xiaojin Pills were measured and the possible markers were screened by spectrum-effect relationship. Further, anti-inflammatory activities of markers were verified and protein interaction network was analyzed, identifying the components of Protocatechuate, Beta-Boswellic acid and Levistilide A as the anti-inflammatory quality markers of Xiaojin Pills. We hope our studies can provide a scientific theoretical basis for accurately quality control of Xiaojin Pills and reasonable suggestions for pharmaceutical companies and new ideas for the quality control of other medicines.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29748583 PMCID: PMC5945850 DOI: 10.1038/s41598-018-25582-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The screening process of Xiaojin Pills’ quality markers based on multi component content determination, COX-2 anti-inflammatory experiment and network interaction analysis.
Figure 2CA result of different batches of Xiaojin Pills based on chemical analysis.
Figure 3Concentration-COX-2 inhibition rate- curves of different Xiaojin Pills’ samples and three compounds. S4 (A), S1 (B), S6 (C), Pro (D), Bet (E) and Lev (F).
Figure 4(A) The protein interaction network of Pro, Bet and Lev; (B) the modules of the protein interaction network of Pro, Bet and Lev.
The main biological process of the modules.
| Cluster | Score | P-value | KEGG pathways |
|---|---|---|---|
| 1 | 14 | 2.6 × 10−6 | Neuroactive liqand-receptor interaction |
| 2 | 12 | 1.3 × 10−11 | Fanconi anemia pathway |
| 3 | 11 | 9.8 × 10−7 | Prostanoid metabolic process |
| 4 | 5.385 | 1.2 × 10−14 | Pathways in cancer |
| 5 | 5 | 6.6 × 10−12 | Steroid hormone biosynthesis |
| 6 | 4 | 1.0 × 10−5 | Arachidonic acid metabolism |
| 7 | 4 | 6.4 × 10−5 | Inflammatory mediator regulation of TRP channels |
| 8 | 4 | 2.9 × 10−6 | Platelet activation, signaling and aggregation |
| 9 | 3.556 | 2.9 × 10−6 | Central carbon metabolism in cancer |
| 10 | 3.333 | 7.2 × 10−4 | Chemokine signaling pathway |
| 11 | 3 | 3.2 × 10−5 | Cell cycle |
Sample information.
| Sample no. | Pharmaceutical factory | Batch no. | Production date |
|---|---|---|---|
| S1 | Jiuzhaigou, Sichuan | 151201 | December 1, 2015 |
| S2 | Jiuzhaigou, Sichuan | 150905 | September 24, 2015 |
| S3 | Jiuzhitang, Schuan | 160601 | June 2, 2016 |
| S4 | Jiuzhitang, Schuan | 151102 | November 16, 2015 |
| S5 | Jiuzhitang, Schuan | 150601.1 | June 8, 2015 |
| S6 | Kaijing, Sichuan | 20151003 | October 28, 2015 |
| S7 | Kaijing, Sichuan | 20160501 | May 1, 2016 |
| S8 | Kaijing, Sichuan | 20160502 | May 2, 2016 |
| S9 | Yongkang, Sichuan | 151009NO.015 | November 4, 2015 |
| S10 | Yongkang, Sichuan | 160806NO.073 | November 3, 2015 |
Summary of molecular weight, multiple-reaction monitoring transitions, DP and CE of the 13 components determined by HPLC-MS/MS.
| Compound | Molecular weight | Monitoring ion | Precursor ion (m/z) | Product ion (m/z) | DP (V) | CE (eV) |
|---|---|---|---|---|---|---|
| AC | 645.7 | ESI+ | 646.3 | 105.1 | 180 | 50 |
| MA | 631.7 | ESI+ | 632.2 | 105.1 | 180 | 46 |
| HA | 615.7 | ESI+ | 616.3 | 105.0 | 180 | 46 |
| BAC | 603.7 | ESI+ | 604.3 | 105.0 | 180 | 45 |
| BMA | 589.7 | ESI+ | 590.3 | 105.0 | 205 | 46 |
| BHA | 573.3 | ESI+ | 574.3 | 105.0 | 200 | 46 |
| Lev | 380.2 | ESI+ | 381.0 | 191.0 | 90 | 10 |
| Ino | 268.2 | ESI+ | 268.9 | 136.9 | 80 | 5 |
| Lig | 190.2 | ESI+ | 191.0 | 90.9 | 100 | 15 |
| Ace | 512.4 | ESI− | 511.3 | 59.1 | 110 | 12 |
| Bet | 456.4 | ESI− | 455.3 | 377.4 | 110 | 48 |
| Fer | 194.1 | ESI− | 193.0 | 133.8 | 100 | 12 |
| Pro | 154.0 | ESI− | 153.0 | 109.0 | 90 | 12 |
Figure 5Typical MRM and chemical structures of the 13 compounds in Xiaojin Pills.